Beone Medicines Ltd-adr (ONC) Quarterly Institutional 13F Update (Q2 2026)

ONC ranks #2252 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

ONC is a top-conviction position for Baker Bros. Advisors LP — at 12.6% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

Ken Griffin has added to its ONC position for two straight quarters, increasing it by $242.6M to reach $412.0M today.

Fidelity has trimmed its ONC position for two straight quarters, cutting it by $506.7M while still holding $706.3M.

ONC is down 0.2% today, but institutions show net buying of $359.0M this quarter — a divergence between today's price move and the underlying institutional flow.

ONC posted net income of $655.7M over the trailing twelve months, and currently trades at a P/E of 845.3.

• Profitable — net income of $655.7M over the trailing twelve months
• Revenue grew 34.3% year over year
• Net income improved year over year, from -$177.6M to $655.7M
• Generated $1.1B in positive operating cash flow
• Current ratio of 3.41x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.88x equity — within a conventional range